Go Shinke, Yutaka Takeda, Yoshiaki Ohmura, Mitsuru Kinoshita, Yoshiteru Katsura, Shu Aoyama, Yukari Kihara, Kiminori Yanagisawa, Shinsuke Katsuyama, Ryo Ikeshima, Masayuki Hiraki, Keijiro Sugimura, Toru Masuzawa, Taishi Hata, Kohei Murata
Tumor mutation burden(TMB)-High is known to potentially elicit a favorable response to immune checkpoint inhibitors. In this report, we present a case of recurrent hilar cholangiocarcinoma with TMB-High, in which we performed comprehensive treatment including immune checkpoint inhibitor pembrolizumab. The patient was a 58-year-old male diagnosed with hilar cholangiocarcinoma who underwent extended right hepatectomy, caudate lobe resection, bile duct excision, and bile duct reconstruction. Postoperatively, peritoneal seeding recurrence and liver metastasis were observed, indicating TMB-High...
December 2023: Gan to Kagaku Ryoho. Cancer & Chemotherapy